Hedera Dx is dedicated to transforming oncology by providing cutting-edge liquid biopsy solutions that improve patient experiences, outcomes, and journeys, as well as healthcare professional experiences, while facilitating the prescription, discovery, and development of the next breakthrough precision oncology therapies.

Hedera Dx aims to transform oncology globally by enabling the routine use of validated liquid biopsies in-house without compliance, bioinformatics, and reporting hurdles at all stages of the disease. They adopt both a customer- and a patient-centric approach, systematically integrating patient-reported outcomes and experiences, patient groups, and customer feedback to deliver products and services that meet the needs of those who need it most.

They offer clinic-ready, NGS-based liquid biopsy solutions that enable non-invasive diagnosis, timely treatment selection, and longitudinal disease monitoring. Their solutions include the registered CE-IVD medical device software Hedera Prime and the pan-cancer targeted assay Hedera Profiling 2 ctDNA test panel. These integrate swiftly into existing laboratory settings to provide fast, locally CE-IVDR-compliant, and clinically actionable NGS-based liquid biopsy solutions processed in-house.

Hedera Dx engages patients actively via the myHedera app and includes their early involvement in studies. This patient-centric initiative aims at driving better oncology care practices and meaningful progress in personalized medicine. They enable cancer patients to access non-invasive blood-based diagnostic tests that facilitate better, timely treatment options selection, ultimately improving patients' experiences and quality of life.

Backed by leading investors, Hedera Dx was established in Switzerland in 2021 by Tommi Lehtonen (CEO, Co-founder), Damien Lapray (CCO, Co-founder, PhD), and Christian Meisel (CMO, Co-founder, MD PhD). The team includes experts in genetics, precision oncology, software, engineering, sales, finance, and bioinformatics.